Effectiveness of a Vitamin Mineral Supplement
Omega-3
Effectiveness of a One-a-Day Cooper Complete Vitamin / Mineral Supplement With or Without Omega-3 Fatty Acid Ingestion
1 other identifier
interventional
75
1 country
1
Brief Summary
The goal of the study is to evaluate the effectiveness of a new one-a-day Cooper complete vitamin supplement with or without a combined omega-3 fatty acid supplement on selected clinical risk factor measures. Participants taking the Cooper Complete one-a-day vitamin plus omega-3 fatty acid will have greater improvement in homocysteine, LDL cholesterol, and C-reactive protein than those taking the other supplements.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1 healthy
Started Sep 2004
Longer than P75 for phase_1 healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 7, 2005
CompletedFirst Posted
Study publicly available on registry
September 12, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2006
CompletedAugust 2, 2012
August 1, 2012
1.5 years
September 7, 2005
August 1, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
homocycsteine
LDL cholesterol oxidation rate
Secondary Outcomes (2)
fasting plasma glucose
C-reactive protein
Study Arms (1)
multivitamin
PLACEBO COMPARATOR1 tablet morning and evening
Interventions
Eligibility Criteria
You may qualify if:
- years of age, maintain current diet and exercise regimen, not currently taking vitamins or agree to stop for 6 weeks
You may not qualify if:
- BMI \<18.5 or \>34.9, recent blood donation, elevated blood pressure, cholesterol, or fasting blood glucose that requires medication, plans to move soon, or pregnant or plans to become pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Cooper Institutelead
- Cooper Cliniccollaborator
Study Sites (1)
The Cooper Institute
Dallas, Texas, 75230, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Conrad Earnest, PhD
The Cooper Institute
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 7, 2005
First Posted
September 12, 2005
Study Start
September 1, 2004
Primary Completion
March 1, 2006
Study Completion
March 1, 2006
Last Updated
August 2, 2012
Record last verified: 2012-08